University of Groningen

Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure

Feng, Siting; Janwanishstaporn, Satit; Teerlink, John R.; Metra, Marco; Cotter, Gad; Davison, Beth; Felker, G. Michael; Filippatos, Gerasimos; Pang, Peter; Ponikowski, Piotr

Published in:
European Journal of Heart Failure

DOI:
[10.1002/ejhf.2012](https://doi.org/10.1002/ejhf.2012)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2021

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Feng, S., Janwanishstaporn, S., Teerlink, J. R., Metra, M., Cotter, G., Davison, B., Felker, G. M., Filippatos, G., Pang, P., Ponikowski, P., Sama, I. E., Voors, A. A., & Greenberg, B. (2021). Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the RELAX-AHF-2 study. *European Journal of Heart Failure*, 23(1), 58-67. <https://doi.org/10.1002/ejhf.2012>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the RELAX-AHF-2 study

Siting Feng^{1,2}, Satit Janwanishstaporn^{1,3}, John R. Teerlink⁴, Marco Metra⁵, Gad Cotter⁶, Beth Davison⁶, G. Michael Felker⁷, Gerasimos Filippatos^{8,9}, Peter Pang¹⁰, Piotr Ponikowski¹¹, Izhia E. Sama¹², Adriaan A. Voors¹², and Barry Greenberg^{1*}

¹Division of Cardiology, University of California, San Diego, CA, USA; ²Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China;

³Faculty of Medicine Siriraj Hospital, Mahidol University, Salaya, Thailand; ⁴Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California, San Francisco, CA, USA; ⁵Cardiology, Department of Medical and Surgical Specialties, Radiologic Sciences, and Public Health, University of Brescia, Brescia, Italy; ⁶Momentum Research, Durham, NC, USA; ⁷Division of Cardiology, Duke University School of Medicine, Durham, NC, USA; ⁸School of Medicine, University of Cyprus, Nicosia, Cyprus; ⁹National and Kapodistrian University of Athens, School of Medicine, Athens, Greece; ¹⁰Department of Emergency Medicine, Indiana University School of Medicine, and the Regenstrief Institute, Indianapolis, IN, USA; ¹¹Department of Heart Diseases, Medical University, Military Hospital, Wrocław, Poland; and ¹²University of Groningen, Groningen, The Netherlands

Received 1 June 2020; revised 12 July 2020; accepted 26 August 2020; online publish-ahead-of-print 9 October 2020

Aims

Whether risk of worsening renal function (WRF) during acute heart failure (AHF) hospitalization or the association between in-hospital WRF and post-discharge outcomes vary according to left ventricular ejection fraction (LVEF) is uncertain. We assessed incidence of WRF, factors related to its development and impact of WRF on post-discharge outcomes across the spectrum of LVEF in patients enrolled in RELAX-AHF-2.

Methods and results

A total of 6112 patients who had LVEF measured on admission and renal function determined prospectively during hospitalization were included. WRF, defined as a rise in serum creatinine ≥ 0.3 mg/dL from baseline through day 5, occurred in 1722 patients (28.2%). Incidence increased progressively from lowest to highest LVEF quartile ($P < 0.001$). After baseline adjustment, WRF risk in Q4 (LVEF $> 50\%$) remained significantly greater than in Q1 (LVEF $\leq 29\%$; hazard ratio 1.2, 95% confidence interval 1–1.43; $P = 0.050$). Age and comorbidity burden including chronic kidney disease increased as LVEF increased. Neither admission haemodynamic abnormalities, extent of diuresis during hospitalization nor residual congestion explained the increased incidence of WRF in patients with higher LVEF. Serelaxin treatment and diuretic responsiveness were associated with reduced risk of WRF in all LVEF quartiles. WRF in patients in the upper three LVEF quartiles increased risk of post-discharge events.

Conclusions

Worsening renal function incidence during AHF hospitalization increases progressively with LVEF. Greater susceptibility of patients with higher LVEF to WRF appears more related to their advanced age and worse underlying kidney function rather than haemodynamic or treatment effects. WRF is associated with increased risk of post-discharge events except in patients in the lowest LVEF quartile.

Keywords

Heart failure • Left ventricular ejection fraction • Worsening renal function • Heart failure hospitalization

*Corresponding author: Advanced Heart Failure Treatment Program, University of California, San Diego Medical Center, 9454 Medical Center Drive, La Jolla, CA 92037-7411, USA. Tel: +1 858 246-2996, Email: bgreenberg@ucsd.edu

Introduction

Worsening renal function (WRF) occurs frequently in patients hospitalized for acute heart failure (AHF).^{1–4} When it occurs, WRF complicates efforts to decongest patients and, in some surveys, has been associated with a less favourable post-discharge outcome.⁴ Although the association between WRF and potential risk factors has been explored,^{5–11} the ability to reliably predict WRF has proven to be a difficult task, likely due to the heterogeneity of the population hospitalized for AHF and the involvement of multiple factors that affect renal function during these episodes.

Left ventricular ejection fraction (LVEF) is available in virtually all patients hospitalized with AHF. We have reported that risk of post-discharge events is increased in patients with heart failure (HF) with reduced ejection fraction (HFrEF) who are hospitalized for AHF.¹² Moreover, recommendations for long-term management are based on classification of patients according to their LVEF.¹³ Although the incidence of WRF appears to be similar in patients with chronic HFrEF and those with HF with preserved ejection fraction (HFpEF),^{14,15} the association between WRF and LVEF during an AHF hospitalization has been inconsistent.^{16–19} These discrepancies are likely due to differences between the populations studied and treatment administered during the hospitalization, reliance on historical rather than current values for LVEF and definitions used for WRF.

Patients in the Relaxin in Acute Heart Failure (RELAX-AHF-2) trial underwent measurement of LVEF at the time of hospital admission but entry was not restricted to a specific level. Renal function was measured on a daily basis during hospitalization, in-hospital course was carefully followed and post-discharge events were adjudicated by an expert independent committee.^{20,21} Thus, RELAX-AHF-2 provided a unique opportunity to assess the incidence of WRF during AHF hospitalization, factors that predispose to its development and the association between WRF and post-discharge outcomes across the full spectrum of LVEF.

Methods

Study design and participants

As described previously, RELAX-AHF-2 was a multicentre, randomized, double-blind, placebo-controlled phase 3 study of serelaxin, a recombinant form of human relaxin-2 as a treatment for AHF.^{20,21} The trial was approved at each study site and written informed consent was obtained from all participants. A total of 6600 who were hospitalized with AHF were recruited between 2 October 2013 and 1 February 2017 at 546 centres in 35 countries. Patients were required to be ≥ 18 years old with all of the following at entry: dyspnoea; congestion on chest radiograph; brain natriuretic peptide (BNP) ≥ 500 pg/mL or N-terminal pro BNP (NT-proBNP) ≥ 2000 pg/mL; systolic blood pressure ≥ 125 mmHg; mostly mild to moderate renal impairment [estimated glomerular filtration rate (eGFR) 25–75 mL/min/1.73 m²] and persistent HF symptoms after initial intravenous loop diuretic treatment equivalent to ≥ 40 mg furosemide. Patients received a 48 h infusion of either serelaxin (30 µg/kg/day) or placebo, in addition to standard care. The main study outcome was neutral for either of the co-primary endpoints of time to first event of cardiovascular death at 180 days or occurrence of worsening HF through day 5.²⁰ Serelaxin

reduced the incidence of WRF, but this effect was consistent across the spectrum of LVEF (online supplementary Figure S1) and there was no significant interaction between Serelaxin and LVEF on WRF (*P*-interaction = 0.553). Thus, the treatment groups were pooled for this analysis.

Left ventricular ejection fraction measurement

In RELAX-AHF-2 patients, LVEF was measured by echocardiography during screening or early post-randomization. The method of LVEF quantification was determined at each study site. Patients without LVEF measurement during index hospitalization were excluded (online supplementary Figure S2). Patients were categorized into quartiles according to LVEF: Q1, 7–29%; Q2, 30–38%; Q3, 39–50% and Q4, $>50\%$. These quartiles were similar to guideline classification of HFrEF, Q1 and Q2, HF with mid-range ejection fraction, Q3 and HFpEF, Q4.

Outcome and clinical assessment

According to protocol, serum creatinine was measured during screening (considered the baseline value) and then daily through day 5 or discharge.²⁰ WRF was defined as any rise in creatinine of ≥ 0.3 mg/dL from baseline through day 5. Patients with missing baseline creatinine were excluded (online supplementary Figure S2). Correlations between LVEF and WRF were assessed analysing LVEF as a categorical variable in quartiles and as a continuous variable.

Physical examination, laboratory tests, and treatment at baseline and daily through day 5 were recorded. Clinical assessment included determination of orthopnoea, oedema, jugular venous pulse, rales and body weight. A composite congestion score ranging from 0 to 8 points was calculated by summing scores for orthopnoea (0–3), peripheral oedema (0–3) and jugular venous pulse (0–2) as described.²² Diuretic response was defined as weight change from baseline through day 5 per 40 mg of intravenous furosemide (or equivalent doses of bumetanide or torsemide) administered during the corresponding period.²³ eGFR was calculated using the simplified Modification of Diet in Renal Disease formula.²⁴ Creatinine and other laboratory tests were performed at each study site using validated assays.

Patients enrolled in RELAX-AHF-2 were assessed at pre-defined clinic visits post-discharge. The main outcome for this analysis was time to first event of the composite of cardiovascular death or HF/renal failure rehospitalization through day 180. Other outcomes of interest were the two components of the composite and all-cause mortality. An independent Clinical Event Committee adjudicated all deaths and rehospitalization events according to pre-defined criteria.^{20,21}

Statistical analysis

Categorical variables are presented as absolute and relative frequencies for baseline characteristics across the LVEF quartiles. Normally and non-normally distributed variables, objectively determined via Shapiro–Wilk testing for normality, are depicted as mean $\pm$ standard deviation and as median (25th, 75th), respectively. Means for continuous variables were compared by ANOVA or Kruskal–Wallis test, while categorical variables were compared by Chi-squared test. A two-tailed *P*-value of ≤ 0.05 was considered statistically significant.

Kaplan–Meier curves for WRF incidence in the LVEF quartiles through day 5 were compared using log-rank test. For multivariable analysis, Cox regression models were used to adjust for effect of

covariates and to calculate hazard ratios (HR). HR between LVEF quartiles were computed using the lowest LVEF (Q1) group as reference. The HRs in multivariable analysis were adjusted using the following variables: study treatment (serelaxin); geographical region; previous hypertension; peripheral arterial disease; atrial fibrillation/flutter; diabetes mellitus; history of HF; systolic blood pressure; pulse rate; respiratory rate; oedema; haemoglobin; baseline eGFR; bilirubin; received intravenous loop diuretic dose in furosemide equivalent at the time of screening; angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB); beta-blockers; mineralocorticoid receptor antagonist (MRA). Selection of variables was based on P -value <0.2 in univariable analysis and from their availability. In multivariable analysis (online supplementary Table S1), the total number was reduced to 4815 patients as participants with missing variables were excluded (online supplementary Figure S3). Smoothing spline functions taking a reference LVEF value of 50% were generated to explore the non-linear relationship between WRF and LVEF as a continuous variable. To determine if the interaction between LVEF and WRF was influenced by in-hospital treatment, changes in creatinine in Q1 and Q4 were compared using repeated mixed effects measures analysis with adjustment for intravenous diuretic, ACEi, ARB, beta-blocker and MRA dose from baseline through day 5 in addition to adjustment for the baseline variables described above.

All analyses were performed using R statistical software version 3.4.3 (R Foundation for Statistical Computing, Vienna, Austria).

Results

Baseline characteristics

Of the 6600 patients randomized in RELAX-AHF-2, 6545 were eligible for this analysis (online supplementary Figure S2). Of these, 417 patients without LVEF measurement at index hospitalization and 16 without baseline creatinine measurement were excluded, leaving a study population of 6112 patients.

Table 1 summarizes baseline characteristics of the patients in each LVEF quartile. Age, likelihood of female sex and history of hypertension and other comorbidities (with the exception of coronary artery disease) increased as the LVEF quartile advanced from lowest to highest. Systolic blood pressure and body mass index also increased progressively as LVEF increased. The baseline congestion composite score dropped as LVEF increased. Likelihood of chronic kidney disease increased and eGFR dropped progressively from lowest to highest LVEF quartile. Loop diuretic dose and likelihood of receiving an MRA were less in patients with higher LVEF whereas ACEi/ARB or beta-blocker usage were similar across the quartiles.

In-hospital treatment and outcomes

Table 2 summarizes in-hospital treatments and outcomes through hospital day 5 according to LVEF. The total dose of both intravenous and oral loop diuretic decreased progressively as LVEF increased. Neither use of intravenous vasoactive therapy nor mechanical circulatory support differed significantly between quartiles. Weight loss and diuretic responsiveness decreased as the LVEF increased while residual congestion was slightly more likely in Q4 patients than in the other quartiles. Systolic blood pressure reduction was greatest in Q1 patients. Creatinine and

blood urea nitrogen increased (and eGFR decreased) in stepwise manner from Q1 to Q4.

While neither worsening HF nor death during the first 5 days of hospitalization differed significantly between the LVEF quartiles, incidence of WRF increased progressively going from 23.1% in Q1 to 34.4% in Q4 ($P < 0.001$).

Association between worsening renal function and left ventricular ejection fraction

To further assess the association between LVEF and WRF, Kaplan–Meier curves for patients in the four quartiles over the first 5 days of hospitalization were compared (Figure 1). The risk of WRF between quartiles differed significantly ($P < 0.0001$ by log-rank test) with Q4 patients experiencing the highest risk. To account for baseline differences between the patients in the quartiles that might have influenced this outcome, the HR for WRF was determined without adjustment (Model 1), after adjustment for age and sex (Model 2) and after adjustment for multiple baseline differences identified during univariate analysis (Model 3). As summarized in online supplementary Table S2, in comparison to Q1, the risk of developing WRF was significantly higher in Q4 in Model 1 [HR 1.57, 95% confidence interval (CI) 1.34–1.84; $P < 0.001$], Model 2 (HR 1.39, 95% CI 1.17–1.64, $P < 0.001$) and Model 3 (HR 1.2, 95% CI 1–1.43, $P = 0.050$). Smooth spline modelling with log-transformed HR for the correlation between LVEF and WRF (depicted in online supplementary Figure S4) demonstrates increased risk for WRF as LVEF increases, although the slope of the association flattens after baseline adjustment. As shown online supplementary Figure S5, change in serum creatine over the 5-day period seen in Q4 patients remained significantly greater than in Q1 patients after adjustment for baseline characteristics and for intravenous diuretic and neurohormonal agent dose.

Factors associated with worsening renal function

Baseline haemodynamic abnormalities, in-hospital diuretic treatment and post-treatment residual congestion have been identified as potential contributors to the development of WRF. Consequently, the association between selected variables reflecting these factors and WRF in patients in the highest and lowest LVEF quartiles were compared to determine whether their impact on WRF differed according to LVEF. As noted in Table 3 and online supplementary Table S1, treatment with serelaxin and greater diuretic responsiveness were associated with reduced risk of WRF but the effects of each were seen across the spectrum of LVEF and there was no interaction of either variable with LVEF. In patients with the lowest LVEF (Q1), rates $>1/3$ way up the lung fields on admission were associated with reduced risk of developing WRF while residual 3+ peripheral oedema and higher clinical congestion score at day 5 were associated with increased risk of WRF. In patients with the highest LVEF (Q4), only higher respiratory rate on admission was associated with increased risk of WRF. When the impact of selected variables on the risk WRF was compared

Table 1 Patient baseline characteristics by left ventricular ejection fraction quartiles

LVEF category	Q1 [7,29] (n = 1543)	Q2 [30,38] (n = 1555)	Q3 [39,50] (n = 1812)	Q4 [51,87] (n = 1202)	P-value
Demographics					
Age (years)	69.0 [61.0;77.0]	74.0 [65.0;80.0]	76.0 [68.0;82.0]	78.0 [70.0;84.0]	<0.001
Male sex	1190 (77.1)	1029 (66.2)	965 (53.3)	471 (39.2)	<0.001
White race	1329 (86.1)	1465 (94.2)	1726 (95.3)	1104 (91.8)	<0.001
Geographical region					<0.001
America/other	471 (30.5)	279 (17.9)	260 (14.3)	287 (23.9)	
Eastern Europe	609 (39.5)	786 (50.5)	954 (52.6)	431 (35.9)	
Western Europe	463 (30.0)	490 (31.5)	598 (33.0)	484 (40.3)	
Medical history					
Hypertension	1293 (84.0)	1374 (88.5)	1684 (93.0)	1143 (95.1)	<0.001
Diabetes mellitus	684 (44.3)	696 (44.8)	851 (47.0)	573 (47.7)	0.199
AF/AFL	672 (43.7)	787 (50.7)	1030 (57.0)	729 (60.7)	<0.001
Peripheral arterial disease	190 (12.5)	208 (13.5)	255 (14.2)	155 (13.0)	0.512
CKD (baseline eGFR <60 mL/min/1.73 m ²)	977 (63.4)	1028 (66.1)	1311 (72.4)	879 (73.2)	<0.001
COPD	234 (15.3)	212 (13.7)	317 (17.6)	198 (16.5)	0.017
Depression	143 (9.31)	96 (6.19)	144 (7.99)	174 (14.5)	<0.001
Prior history of HF	1201 (77.9)	1203 (77.4)	1314 (72.5)	818 (68.1)	<0.001
Ischaemic cause of HF	679 (56.7)	740 (61.6)	735 (56.0)	293 (35.8)	<0.001
NYHA FC 1-month prior to index admission					<0.001
I	34 (2.88)	57 (4.82)	56 (4.34)	51 (6.37)	
II	405 (34.3)	442 (37.4)	530 (41.1)	359 (44.8)	
III	581 (49.2)	570 (48.2)	586 (45.4)	324 (40.4)	
IV	160 (13.6)	114 (9.64)	118 (9.15)	67 (8.36)	
Physical examination					
BMI (kg/m ²)	28.1 [24.8;32.1]	28.7 [25.2;32.6]	29.1 [25.6;33.5]	30.1 [25.9;34.9]	<0.001
Pulse rate (bpm)	84.0 [73.0;95.0]	81.0 [70.0;93.0]	78.0 [68.0;90.0]	75.0 [65.0;88.0]	<0.001
Respiratory rate (breaths/min)	21.0 [18.0;24.0]	21.0 [18.0;24.0]	21.0 [18.0;24.0]	20.0 [18.0;24.0]	0.015
Systolic blood pressure (mmHg)	134 [128;143]	138 [130;148]	140 [132;152]	144 [134;158]	<0.001
Diastolic blood pressure (mmHg)	81.0 [73.0;91.0]	80.0 [72.0;89.0]	79.0 [70.0;87.0]	76.0 [67.0;86.0]	<0.001
Oedema					0.004
0	255 (17.3)	199 (13.5)	236 (14.0)	174 (15.4)	
1+	417 (28.3)	436 (29.7)	542 (32.2)	330 (29.3)	
2+	472 (32.1)	542 (36.9)	562 (33.4)	413 (36.6)	
3+	328 (22.3)	292 (19.9)	341 (20.3)	211 (18.7)	
Jugular venous pulse					0.001
<6 cm	334 (24.4)	353 (26.2)	445 (29.0)	308 (30.0)	
6–10 cm	630 (46.1)	666 (49.4)	715 (46.6)	485 (47.3)	
>10 cm	403 (29.5)	330 (24.5)	373 (24.3)	233 (22.7)	
Orthopnoea					<0.001
None	58 (3.94)	44 (3.00)	69 (4.10)	40 (3.55)	
1 Pillow (10 cm)	205 (13.9)	230 (15.7)	323 (19.2)	193 (17.1)	
2 Pillows (20 cm)	692 (47.0)	728 (49.6)	767 (45.6)	586 (52.0)	
>30°	517 (35.1)	467 (31.8)	522 (31.1)	308 (27.3)	
Rales (yes)	1379 (93.7)	1388 (94.5)	1589 (94.6)	1058 (93.8)	0.668
Composite congestion score (mean ± SD)	4.76 (1.81)	4.72 (1.74)	4.57 (1.80)	4.54 (1.76)	0.002
Laboratory measurements					
BNP (pg/mL)	1548 [956;2604]	1207 [817;1872]	998 [680;1487]	882 [594;1320]	<0.001
NT-proBNP (pg/mL)	7843 [4663;13 501]	6877 [4092;12 850]	5460 [3377;9000]	4339 [2790;7475]	<0.001
BUN(mg/dL)	24.3 [18.5;31.9]	24.1 [18.7;31.3]	24.2 [18.6;32.2]	24.3 [18.7;33.0]	0.722
Creatinine (μmol/L)	116 [100;141]	113 [97.2;137]	113 [94.9;140]	110 [92.0;138]	<0.001
eGFR (mL/min/1.73 m ²)	53.0 [42.0;64.0]	52.4 [41.0;64.0]	50.0 [39.0;61.0]	48.9 [38.0;60.0]	<0.001

Table 1 (Continued)

LVEF category	Q1 [7,29] (n = 1543)	Q2 [30,38] (n = 1555)	Q3 [39,50] (n = 1812)	Q4 [51,87] (n = 1202)	P-value
BUN:creatinine ratio	73.8 [58.7;90.6]	75.2 [60.9;94.2]	76.8 [62.3;94.2]	78.0 [63.8;96.7]	<0.001
Total bilirubin (μmol/L)	17.0 [11.8;24.5]	14.6 [9.58;21.4]	12.4 [8.55;18.8]	12.0 [8.55;17.2]	<0.001
Haemoglobin (g/L)	133 [119;145]	130 [116;143]	124 [110;138]	119 [106;132]	<0.001
Baseline HF medications					
Oral loop diuretic daily dose, mg of furosemide equivalent, mean ± (SD)	61.6 (57.6)	53.6 (57.0)	53.1 (58.9)	50.8 (56.8)	<0.001
ACEi or ARB	973 (68.3)	1029 (70.7)	1207 (69.6)	804 (69.1)	0.570
Beta-blockers	1058 (74.2)	1103 (75.8)	1297 (74.8)	878 (75.5)	0.782
MRA	590 (41.4)	506 (34.8)	461 (26.6)	201 (17.3)	<0.001
Calcium channel blockers	157 (11.0)	263 (18.1)	486 (28.0)	431 (37.1)	<0.001
Digoxin	230 (16.1)	210 (14.4)	214 (12.3)	125 (10.7)	<0.001

Categorical variables are presented as *n* (%), continuous data as median [25th–75th percentile] unless specified.

ACEi, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; AFL, atrial flutter; ARB, angiotensin receptor blocker; BMI, body mass index; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate (by simplified Modification of Diet in Renal Disease formula); HF, heart failure; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro brain natriuretic peptide; NYHA FC, New York Heart Association functional class; SD, standard deviation.

between LVEF quartiles, the only significant interaction was for baseline rates, which was associated with reduced risk of WRF in Q1 and nominally higher risk in Q4. Modest interactions towards higher baseline respiratory rate ($P = 0.051$) associated with higher risk of WRF in Q4 than in Q1 and greater risk of WRF for residual congestion in Q1 than Q4 were noted. Neither baseline natriuretic peptide levels nor haemoconcentration (as evidenced by change in haemoglobin) was associated with WRF risk in either quartile and there was no significant interaction of the impact of these variables on WRF and LVEF. As shown in online supplementary Figure S5, increases in creatinine were greater in patients in Q4 than in Q1 at all time points. A significant interaction between WRF and LVEF persisted after repeated mixed effects measures analysis which incorporated dose of intravenous loop diuretics and neurohormonal agents as well as the other covariates described previously.

Association between worsening renal function and post-discharge events

As shown in online supplementary Table S3, patients who experienced WRF during index hospitalization were at increased risk for the composite of cardiovascular mortality or HF/renal failure rehospitalization through day 180 (HR 1.18, 95% CI 1.05–1.31; $P = 0.004$). This was driven predominantly by increased risk for cardiovascular death (HR 1.25, 95% CI 1.04–1.50; $P = 0.018$). WRF during the first 5 days of hospitalization was also associated with increased risk for all-cause mortality at 180 days (HR 1.29, CI 1.10–1.51; $P = 0.002$). Occurrence of the 180 composite end-point according to incident WRF during the index hospitalization is shown for each quartile in Figure 2. While occurrence of WRF did not significantly affect this outcome in patients in the lowest LVEF quartile, patients in Q2–4 who developed WRF in hospital were at higher risk for events than patients without WRF. As shown in

Table 4, there was a significant interaction between WRF and LVEF for the composite outcome, with similar directional trends for both components.

Discussion

In this analysis of RELAX-AHF-2 results, WRF occurred in over a quarter of patients within the first 5 days of an AHF hospitalization, with the incidence increasing progressively from 23.1% of patients in the lowest quartile to 34.4% in the highest. Differences in the incidence of WRF between patients in the lowest and highest LVEF quartile persisted after adjustment for baseline characteristics and treatment during hospitalization. Our results suggest that more advanced age and worse underlying kidney function on hospital admission rather than more severe baseline haemodynamic abnormalities, more extensive diuresis or greater blood pressure reduction during hospitalization or residual congestion after 5 days of treatment may explain the greater susceptibility of patients with higher LVEF to develop WRF during an AHF hospitalization. Although serelaxin treatment and greater diuretic responsiveness were associated with reduced WRF incidence, their effects were consistent across the entire spectrum of LVEF. Our results also show that WRF during AHF hospitalization is associated with increased risk for post-discharge events except in patients in the lowest LVEF quartile.

Previous reports assessing the association between LVEF and risk of WRF in patients with HF have had discrepant results. In patients with chronic HF, those with HFrEF have a greater likelihood of developing WRF over time than do patients with HFpEF.^{25,26} In hospitalized patients with AHF, however, the relationship between LVEF and WRF has been inconsistent. A retrospective study of 363 patients with AHF reported that the incidence of WRF was increased in patients with higher baseline LVEF values.¹⁸ An analysis

Table 2 In-hospital treatment, change from baseline and in-hospital outcomes

	LVEF category			P-value
	Q1 [7,29] (n = 1543)	Q2 [30,38] (n = 1555)	Q3 [39,50] (n = 1812)	Q4 [51,87] (n = 1202)
Total IV loop diuretics dose through day 5 (mg)	160 [80.0;300]	160 [80.0;280]	140 [60.0;260]	140 [40.0;260]
Total oral loop diuretics through day 5 (mg)	300 [200;460]	280 [180;440]	260 [180;400]	260 [160;400]
IV vasoactive therapy or MCS, n (%)	89 (5.75)	100 (6.43)	129 (7.11)	90 (7.44)
Congestion status at day 5				
Weight change at day 5 (% change)	-3.20 [-5.80;-1.20]	-3.00 [-5.00;-1.20]	-3.00 [-5.00;-1.20]	-2.50 [-5.00;-1.00]
Diuretic response through day 5 (kg of weight change per 40 mg of furosemide)	-0.67 [-1.50;-0.23]	-0.60 [-1.33;-0.24]	-0.67 [-1.33;-0.25]	-0.55 [-1.33;-0.17]
Haemoconcentration (increase of Hb) at day 5, n (%)	563 (45.5)	596 (45.1)	747 (48.2)	494 (49.5)
Oedema 2+ or 3+ at day 5, n (%)	496 (32.3)	474 (30.6)	571 (31.7)	423 (35.1)
Jugular venous pulse > 10 cm at day 5, n (%)	98 (6.79)	119 (8.24)	113 (6.72)	101 (8.98)
Orthopnoea (2 pillows or >30°) at day 5, n (%)	203 (16.8)	209 (11.6)	214 (13.8)	233 (15.2)
Rales at day 5, n (%)	359 (23.4)	314 (20.3)	417 (23.1)	327 (27.2)
Any persisting congestion at day 5, n (%)	675 (45.7)	598 (40.6)	751 (43.7)	563 (48.8)
Change in haemodynamics at day 5 (% change from baseline values)				
Systolic blood pressure	-12.16 [-18.90;-5.11]	-10.16 [-17.30;-3.70]	-10.00 [-17.29;-3.12]	-10.89 [-18.63;-2.12]
Diastolic blood pressure	-11.39 [-21.79;0.00]	-9.09 [-19.54;1.29]	-7.14 [-17.78;3.01]	-6.98 [-18.60;5.35]
Respiration rate	-17.65 [-29.52;-5.56]	-16.67 [-28.00;-7.14]	-18.18 [-30.00;-5.88]	-16.67 [-27.27;0.00]
Change in renal function through day 5 (% change from baseline values)				
eGFR	0.00 [-15.22;17.7]	-2.28 [-17.56;15.6]	-4.45 [-19.08;12.2]	-5.08 [-21.61;10.0]
Serum creatinine	0.00 [-12.89;15.3]	1.98 [-12.14;18.1]	4.02 [-9.02;20.0]	4.48 [-8.05;24.1]
Blood urea nitrogen	11.4 [-11.94;45.9]	16.3 [-9.81;52.1]	19.2 [-6.88;51.7]	21.8 [-6.74;57.1]
In-hospital outcomes				
Length of stay (days)	6.67 [4.96;9.84]	6.86 [5.06;9.93]	6.87 [5.12;9.97]	6.85 [5.06;10.6]
Worsening HF through day 5, n (%)	101 (6.52)	115 (7.39)	122 (6.72)	100 (8.27)
Death through day 5, n (%)	7 (0.45)	7 (0.45)	14 (0.77)	4 (0.33)
WRF through day 5, n (%)	356 (23.1)	419 (27.1)	532 (29.4)	415 (34.4)

Continuous data are presented as median [25th–75th percentile]. Doses of loop diuretic are furosemide equivalent.

eGFR, estimated glomerular filtration rate (by simplified Modification of Diet in Renal Disease formula); Hb, haemoglobin; IV, intravenous; LVEF, left ventricular ejection fraction; MCS, mechanical circulatory support; WRF, worsening renal function.

of 105 388 patients in the ADHERE registry also reported that WRF incidence during HF hospitalization was significantly higher in patients with preserved LVEF than in patients with severely reduced LVEF¹⁶ but it is difficult to compare these findings to results of the present study due to differences in the definition of WRF. Results from the Korean AHF Registry suggested that WRF was more frequent in patients with HFrEF than in those with HFpEF (56.9% vs. 50.3%).¹⁹ However, after multivariable analysis which took into account differences in baseline creatinine and treatment with inotropic agents, there was a trend towards lower

risk for WRF (odds ratio 0.84, $P = 0.077$) in HFrEF compared to HFpEF patients. In contrast to these results, a prospective study from a tertiary HF referral centre in Italy reported that reduced LVEF was independently related to higher risk of WRF,¹⁷ but this population may have been skewed towards inclusion of more advanced HFrEF as nearly a third of the patients required inotrope support. Although the present analysis shows that risk of WRF increases as baseline LVEF increases, it is important to recognize that RELAX-AHF-2 excluded patients with baseline systolic blood pressures <125 mmHg²¹ who might have been at higher risk of developing WRF. This possibility is supported by an analysis of RELAX-AHF-eligible patients in the ADHERE registry showing that they had better renal function than non-eligible patients.²⁷

Examination of patient baseline characteristics and hospital course provide potential clues why risk of developing WRF increased with higher LVEF. The age of the patients and burden of comorbidities, including chronic kidney disease, of patients enrolled in RELAX-AHF-2 increased as LVEF increased while responsiveness to diuretics, another indicator of renal function, decreased. Patients with higher LVEF, however, were not more severely congested at the time of index hospitalization nor did not have lower blood pressures on admission. These patients were not more extensively diuresed nor did they experience either greater depletion of intravascular volume or reduction in blood pressure than did patients with lower LVEF levels as evidenced by the fact that total diuretic dose, weight loss in hospital and reduction in systolic or diastolic blood pressures were less in Q4 than in Q1 patients while haemoconcentration did not differ significantly between quartiles. Although residual congestion was more common in Q4 than in Q1 patients, it was not a significant predictor of WRF in the higher LVEF patients. Furthermore, the greater increase in creatinine seen in Q4 than in Q1 patients persisted after accounting for intravenous diuretic and neurohormonal agent

Table 3 Univariate analysis of variables during hospitalization on worsening renal function outcome in Q1 vs. Q4 and interaction analysis with left ventricular ejection fraction quartiles

	LVEF Q1		LVEF Q4		P-value for interaction
	HR [95% CI]	P-value	HR [95% CI]	P-value	
Baseline JVP >10 cm	1.08 [0.85;1.38]	0.510	1.00 [0.78;1.29]	0.980	0.721
Rales $\geq 1/3$ at baseline	0.56 [0.39;0.81]	0.002	1.34 [0.83;2.15]	0.226	0.008
Respiration rate (breaths/min)	0.99 [0.97;1.01]	0.365	1.02 [1.00;1.05]	0.038	0.051
Baseline NT-proBNP (pmol/L)	1.00 [1.00;1.00]	0.384	1.00 [1.00;1.00]	0.547	0.325
Baseline eGFR ≥ 60 mL/min/1.73 m ²	1.00 [0.81;1.25]	0.972	0.79 [0.63;1.00]	0.047	0.135
Serelaxin treatment	0.69 [0.56;0.86]	0.001	0.80 [0.66;0.97]	0.022	0.426
IV loop diuretics through day 5 (total furosemide dose equivalent) (mg)	1.00 [1.00;1.00]	0.034	1.00 [1.00;1.00]	<0.001	0.551
Diuretic response at day 5 (kg of body weight change per 40 mg furosemide)	1.09 [1.02;1.18]	0.015	1.08 [1.03;1.14]	0.002	0.952
No change or decrease of Hb at day 5	1.02 [0.81;1.28]	0.895	1.11 [0.91;1.37]	0.304	0.665
Oedema at day 5: 3+	1.59 [1.11;2.28]	0.011	1.08 [0.77;1.52]	0.652	0.104
Residual clinical congestion composite score at day 5	1.08 [1.02;1.13]	0.003	1.01 [0.97;1.06]	0.603	0.078

CI, confidence interval; eGFR, estimated glomerular filtration rate; Hb, haemoglobin; HR, hazard ratio; IV, intravenous; JVP, jugular venous pulse; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro brain natriuretic peptide.

Figure 2 Occurrence of composite endpoint of cardiovascular mortality and heart failure/renal failure hospitalization over 180 days (COMP180) by worsening renal function (WRF) status per left ventricular ejection fraction (LVEF) quartiles. KM, Kaplan–Meier.

Table 4 Association between worsening renal function and long-term outcomes focus groups Q4 and Q1 with interaction test

WRF status: WRF (no WRF as reference)	HR Q1 (95% CI)	P-value	HR Q4 (95% CI)	P-value	P-value for interaction (Q1 vs. Q4)
Composite endpoint of CV death or HF/RF rehospitalization through day 180	0.92 [0.73;1.16]	0.481	1.34 [1.05;1.70]	0.016	0.027
Rehospitalization due to HF/RF through day 180	0.85 [0.65;1.11]	0.228	1.21 [0.92;1.60]	0.167	0.079
CV death through day 180	0.97 [0.66;1.42]	0.867	1.54 [1.01;2.33]	0.043	0.099
All death through day 180	0.98 [0.69;1.38]	0.894	1.28 [0.91;1.80]	0.149	0.253

CI, confidence interval; CV, cardiovascular; HF, heart failure, HR, hazard ratio; RF, renal failure; WRF, worsening renal function.

dose during the 5-day period. These findings argue against the possibility that the increased incidence of WRF in patients with higher LVEF was related to baseline haemodynamic abnormalities, use of higher doses of diuretics, greater depletion of intravascular volume, reduced renal perfusion pressure, or more severe residual congestion. While both serelaxin treatment and diuretic responsiveness were associated with reduced likelihood of developing WRF, both were equally protective across the spectrum of LVEF

and there was no interaction between LVEF and either variable for WRF risk. Our results are most consistent with the possibility that the increased vulnerability of patients with higher LVEF for developing WRF was due to their increased age and more severely impaired baseline renal function.

The association between WRF during an AHF hospitalization and clinical events post-discharge is controversial with some studies reporting that patients who experience WRF are at

increased risk^{28–30} while others suggest that this association depends on the clinical context. Our results are consistent with a previous registry-based study which demonstrated that WRF is a stronger predictor of 1-year mortality in patients with HFpEF than in those with HFrEF.¹⁹ Although the reason for the significant association between WRF and 180-day outcome in the three highest LVEF quartiles but not the lowest is uncertain, it could be due to different mechanisms involved in the development of WRF between patients in these groups.^{31–34} It is possible that the rise in creatinine in patients in Q1 patients was related to a reduction in preload that in the setting of severely reduced LVEF may have had effects on cardiac function that translated to long-term clinical benefits. Further studies to sort out the underlying mechanisms of WRF in patients during an AHF hospitalization are needed to better understand the pathophysiology involved. Interestingly, treatment with serelaxin reduced the incidence of WRF, an effect that was seen in patients across the spectrum of LVEF. This result is consistent with a previous study that reported renal protective effects of serelaxin in patients hospitalized with AHF³⁵ but unfortunately this effect did not translate to long-term clinical benefit as the results of RELAX-AHF-2 were neutral.²⁰

Strengths of this analysis include the fact that RELAX-AHF-2 enrolled patients according to strict criteria for AHF, including elevated natriuretic peptide levels. LVEF was measured on admission to hospital, thus capturing the state of the patient at the time of index event. Renal function and other variables were prospectively collected daily through day 5. The association between LVEF and WRF was assessed using LVEF as both a categorical and a continuous variable to minimize bias due to the use of arbitrary LVEF cut-points. Finally, post-discharge events were pre-defined and adjudicated by an independent committee that was blinded to study treatment.

Study limitations

In this post-hoc analysis of RELAX-AHF-2 data, confounding variables that were not identified or considered may have affected the results. Entry criteria which excluded patients with systolic blood pressure <125 mmHg or receiving inotrope treatment may have reduced the number of patients with WRF, particularly in the lower LVEF quartiles. Since patients were required to have an eGFR 25–75 mL/min/1.73 m², our findings are most applicable to patients who have evidence of mild to moderate chronic kidney disease during AHF hospitalization. LVEF measurements and serum creatinine values were accessed at local study sites rather than at a central core laboratory. The evaluation of some clinical signs is subjective and considerable interobserver variation has been noted. A change in the absolute creatinine value was used to define WRF and this approach might have failed to detect WRF in elderly cachectic patients with lower baseline creatinine level. Absence of variables from multivariable analysis resulted in a substantial reduction in patient numbers and some important in-hospital variables including inotrope use^{19,36} and changes in neurohormonal blocking medications were not included due to incompleteness of data.

Conclusion

In patients hospitalized for AHF in RELAX-AHF-2, WRF occurred commonly, with incidence rising from lowest to highest LVEF quartile. There was no evidence, however, that factors commonly recognized as influencing kidney function in this setting (e.g. baseline haemodynamic abnormalities, in-hospital diuretic treatment, post-treatment residual congestion) were more prominent in patients in the higher LVEF quartiles. Rather, the increased susceptibility of these patients for developing WRF appears to be related to their more advanced age and worse baseline kidney function. While WRF in hospital was not associated with post-discharge outcomes in patients in the lowest LVEF quartile, it did portend a less favourable course in patients in the upper quartiles. How WRF impacts the post-discharge course in these patients and whether interventions can both mitigate the increased risk for development of WRF and improve long-term outcomes in this vulnerable population requires further study.

Conflict of interest: B.G. served on the Executive Committee for the RELAX-AHF-2 study and consulted for the following companies: ACI, Actelion, Akcea, Amgen, Bayer, EBR systems, Ionis, Janssen, Merck, Myokardia, Relypsa, Rocket, Sanofi, Vifor, Viking, Zensun. All other authors have nothing to disclose.

Supplementary Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

References

1. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, Krumholz HM. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. *J Am Coll Cardiol* 2006;**47**:1987–1996.
2. Cowie MR, Komajda M, Murray-Thomas T, Underwood J, Ticho B; POSH Investigators. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). *Eur Heart J* 2006;**27**:1216–1222.
3. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J; ADHERE Scientific Advisory Committee and Investigators. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. *J Card Fail* 2007;**13**:422–430.
4. Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. *Eur Heart J* 2014;**35**:455–469.
5. Mentz RJ, O'Connor CM. Pathophysiology and clinical evaluation of acute heart failure. *Nat Rev Cardiol* 2016;**13**:28–35.
6. Ronco C, Ciccoira M, McCullough PA. Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. *J Am Coll Cardiol* 2012;**60**:1031–1042.
7. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WH. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. *J Am Coll Cardiol* 2009;**53**:589–596.
8. Nohria A, Hasselblad V, Stebbins A, Pauly DF, Fonarow GC, Shah M, Yancy CW, Califf RM, Stevenson LW, Hill JA. Cardiorenal interactions: insights from the ESCAPE trial. *J Am Coll Cardiol* 2008;**51**:1268–1274.
9. ter Maaten JM, Valente MA, Damman K, Hillege HL, Navis G, Voors AA. Diuretic response in acute heart failure – pathophysiology, evaluation, and therapy. *Nat Rev Cardiol* 2015;**12**:184–192.
10. Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. *Circulation* 2010;**122**:265–272.

11. Aronson D, Burger AJ. The relationship between transient and persistent worsening renal function and mortality in patients with acute decompensated heart failure. *J Card Fail* 2010;**16**:541–547.
12. Janwanishataporn S, Feng S, Teerlink J, Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Pang P, Ponikowski P, Severin T, Gimpelewicz C, Holbro T, Chen CW, Sama I, Voors AA, Greenberg BH. Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX-AHF-2 trial. *Eur J Heart Fail* 2020;**22**:726–738.
13. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2016;**18**:891–975.
14. Damman K, Perez AC, Anand IS, Komajda M, McKelvie RS, Zile MR, Massie B, Carson PE, McMurray JJ. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. *J Am Coll Cardiol* 2014;**64**:1106–1113.
15. Damman K, Solomon SD, Pfeffer MA, Swedberg K, Yusuf S, Young JB, Rouleau JL, Granger CB, McMurray JJ. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. *Eur J Heart Fail* 2016;**18**:1508–1517.
16. Sweitzer NK, Lopatin M, Yancy CW, Mills RM, Stevenson LW. Comparison of clinical features and outcomes of patients hospitalized with heart failure and normal ejection fraction (> or =55%) versus those with mildly reduced (40% to 55%) and moderately to severely reduced (<40%) fractions. *Am J Cardiol* 2008;**101**:1151–1156.
17. Metra M, Nodari S, Parrinello G, Bordonali T, Bugatti S, Danesi R, Fontanella B, Lombardi C, Milani P, Verzura G, Cotter G, Dittrich H, Massie BM, Dei Cas L. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. *Eur J Heart Fail* 2008;**10**:188–195.
18. Gannon SA, Mukamal KJ, Chang JD. Echocardiographic predictors of change in renal function with intravenous diuresis for decompensated heart failure. *ESC Heart Fail* 2018;**5**:858–863.
19. Kang J, Park JJ, Cho YJ, Oh IY, Park HA, Lee SE, Kim MS, Cho HJ, Lee HY, Choi JO, Hwang KK, Kim KH, Yoo BS, Kang SM, Baek SH, Jeon ES, Kim JJ, Cho MC, Chae SC, Oh BH, Choi DJ. Predictors and prognostic value of worsening renal function during admission in HFpEF versus HFrEF: data from the KorAHF (Korean Acute Heart Failure) registry. *J Am Heart Assoc* 2018;**7**:e007910.
20. Metra M, Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Pang PS, Ponikowski P, Voors AA, Adams KF, Anker SD, Arias-Mendoza A, Avendano P, Bacal F, Bohm M, Bortman G, Cleland JG, Cohen-Solal A, Crespo-Leiro MG, Dorobantu M, Echeverria LE, Ferrari R, Golland S, Goncalvesova E, Goudev A, Kober L, Lema-Osores J, Levy PD, McDonald K, Manga P, Merkely B, Mueller C, Pieske B, Silva-Cardoso J, Spinar J, Squire I, Stepinska J, Van Mieghem W, von Lewinski D, Wikstrom G, Yilmaz MB, Hagner N, Holbro T, Hua TA, Sabarwal SV, Severin T, Szczesny P, Gimpelewicz C; RELAX-AHF-2 Committees Investigators. Effects of serelaxin in patients with acute heart failure. *N Engl J Med* 2019;**381**:716–726.
21. Teerlink JR, Voors AA, Ponikowski P, Pang PS, Greenberg BH, Filippatos G, Felker GM, Davison BA, Cotter G, Gimpelewicz C, Boer-Martins L, Wernsing M, Hua TA, Severin T, Metra M. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. *Eur J Heart Fail* 2017;**19**:800–809.
22. Rubio-Gracia J, Demissei BG, Ter Maaten JM, Cleland JG, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison BA, Givertz MM, Bloomfield DM, Dittrich H, Damman K, Perez-Calvo JL, Voors AA. Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. *Int J Cardiol* 2018;**258**:185–191.
23. Valente MA, Voors AA, Damman K, Van Veldhuisen DJ, Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, Fiuza M, Dittrich HC, Hillege HL. Diuretic response in acute heart failure: clinical characteristics and prognostic significance. *Eur Heart J* 2014;**35**:1284–1293.
24. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med* 1999;**130**:461–470.
25. de Silva R, Nikitin NP, Witte KK, Rigby AS, Goode K, Bhandari S, Clark AL, Cleland JG. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. *Eur Heart J* 2006;**27**:569–581.
26. Khan NA, Ma I, Thompson CR, Humphries K, Salem DN, Sarnak MJ, Levin A. Kidney function and mortality among patients with left ventricular systolic dysfunction. *J Am Soc Nephrol* 2006;**17**:244–253.
27. Wang TS, Hellkamp AS, Patel CB, Ezekowitz JA, Fonarow GC, Hernandez AF. Representativeness of RELAX-AHF clinical trial population in acute heart failure. *Circ Cardiovasc Qual Outcomes* 2014;**7**:259–268.
28. Krumholz HM, Chen YT, Vaccarino V, Wang Y, Radford MJ, Bradford WD, Horwitz RJ. Correlates and impact on outcomes of worsening renal function in patients > or =65 years of age with heart failure. *Am J Cardiol* 2000;**85**:1110–1113.
29. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Secular trends in renal dysfunction and outcomes in hospitalized heart failure patients. *J Card Fail* 2006;**12**:257–262.
30. Metra M, Davison B, Bettari L, Sun H, Edwards C, Lazzarini V, Piovanelli B, Carubelli V, Bugatti S, Lombardi C, Cotter G, Dei Cas L. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. *Circ Heart Fail* 2012;**5**:54–62.
31. ter Maaten JM, Damman K, Verhaar MC, Paulus WJ, Duncker DJ, Cheng C, van Heerebeek L, Hillege HL, Lam CSP, Navis G, Voors AA. Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. *Eur J Heart Fail* 2016;**18**:588–598.
32. Takei M, Kohsaka S, Shiraishi Y, Goda A, Izumi Y, Yagawa M, Mizuno A, Sawano M, Inohara T, Kohno T, Fukuda K, Yoshikawa T; West Tokyo Heart Failure Registry Investigators. Effect of estimated plasma volume reduction on renal function for acute heart failure differs between patients with preserved and reduced ejection fraction. *Circ Heart Fail* 2015;**8**:527–532.
33. Ahmad T, Jackson K, Rao VS, Tang WH, Brisco-Bacik MA, Chen HH, Felker GM, Hernandez AF, O'Connor CM, Sabbiseti VS, Bonventre JV, Wilson FP, Coca SG, Testani JM. Worsening renal function in patients with acute heart failure undergoing aggressive diuresis is not associated with tubular injury. *Circulation* 2018;**137**:2016–2028.
34. Dupont M, Shrestha K, Singh D, Awad A, Kovach C, Scarpino M, Maroo AP, Tang WH. Lack of significant renal tubular injury despite acute kidney injury in acute decompensated heart failure. *Eur J Heart Fail* 2012;**14**:597–604.
35. Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF, Dorobantu MI, Grinfeld L, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Prescott MF, Edwards C, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin T, Teerlink JR. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. *J Am Coll Cardiol* 2013;**61**:196–206.
36. Testani JM, McCauley BD, Kimmel SE, Shannon RP. Characteristics of patients with improvement or worsening in renal function during treatment of acute decompensated heart failure. *Am J Cardiol* 2010;**106**:1763–1769.